Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update

24.03.2023 - - Enrollment Nearing Completion in Human Acellular Vessel (HAV) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients - Multiple publications and scientific meeting presentations highlighting ...

Related Keywords

Kyiv ,Kyyiv ,Misto ,Ukraine ,Munich ,Bayern ,Germany ,Israel ,Illinois ,United States ,Chicago ,Ukrainian ,American ,Oleksandr Sokolov ,Oleksandr Stanko ,Laura Niklason ,Alanp Kypson ,Vasyl Shaprynskyi ,Joyce Allaire ,Kaplan Meier ,Alpha Healthcare Acquisition Corp ,Company Phase ,Humacyte Inc ,Xvi Congress ,Nasdaq ,American Heart Association ,Drug Administration ,Fresenius Medical Care ,Lifesci Advisors ,Executive Officer ,Biologics License Application ,Recent Corporate ,Vascular Surgery ,Year Outcomes ,Human Tissue Engineered Blood Vessels ,Peripheral Arterial Bypass ,Vascular Surgeons ,Munich Vascular ,American Heart ,Scientific Sessions ,Year Ended ,Alpha Healthcare ,Call Details ,Medicine Advanced Therapy ,Annual Report ,Investor Contact ,Media Contact ,Consolidated Statements ,Comprehensive Income ,